ReviewFrontiers in immunology2026
Bone marrow microenvironment reprogramming in myelodysplastic neoplasms: from pathological mechanisms to targeted therapeutic strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic Neoplasms (MDS) are a group of clonal hematopoietic malignancies originating from hematopoietic stem cells. Their pathogenesis involves not only genetic abnormalities in hematopoietic cells but is also closely associated with functional dysregulation of the bone marrow microenvironment (BMME). In MDS, both the heterogeneous cellular populations and non-cellular components of the BMME exhibit significant dysfunction. Aberrant BMME components drive the initiation and progression of the disease through complex intercellular interactions. In-depth research into its pathological features and molecular mechanisms is of great significance for developing effective targeted therapeutic strategies. In recent years, novel treatment strategies based on BMME regulation have made significant progress, including immunomodulators, epigenetic regulators, molecularly targeted drugs, and cell therapies, providing new insights for improving the clinical outcomes of MDS patients. This article systematically reviews the pathological features of the BMME in MDS and its key molecular mechanisms in disease development, and discusses the latest clinical research advances in BMME-targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.